Effect of combined oral contraceptives on breast epithelial proliferation in young women

Breast Journal

Volumn 14, Issue 5, 2008, Pages 450-455

  Narvaiza, Debora Garcia Y ^b   Navarrete, Maria Alicia H ^a,b   Falzoni, Roberto ^c   Maier, Carolina M ^d   Nazário, Afonso C P ^b  

^a Federal University of São Paulo ^*  (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d APC Pathology   (Brazil)

Author keywords

Combined oral contraceptives; Ki 67; Mammary gland; Menstrual cycle

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; KI 67 ANTIGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADOLESCENT; ADULT; ARTICLE; BREAST EPITHELIUM; BREAST FIBROADENOMA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SAFETY; EPITHELIUM CELL; FEMALE; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PROGESTERONE BLOOD LEVEL; PROGESTERONE RELEASE;

ADOLESCENT; ADULT; AGE FACTORS; BIOPSY, NEEDLE; BREAST; CELL PROLIFERATION; CONTRACEPTIVES, ORAL, COMBINED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; LUTEAL PHASE; MENSTRUAL CYCLE; PROBABILITY; PROGESTERONE; RADIOIMMUNOASSAY; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 51349128262     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2008.00621.x     Document Type: Article

References (37)

1. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004 190 (Suppl. 4 S5 22.
2. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001 344 : 276 85.
3. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000 50 : 7 33.
4. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975 55 : 231 73.
5. de Lignieres B, Silberstein S. Pharmacodynamics of oestrogens and progestogens. Cephalalgia 2000 20 : 200 7.
6. Fowke JH, Shu XO, Dai Q, et al. Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2004 13 : 1308 15.
7. Isaksson E, von Schoultz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001 65 : 163 9.
8. Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992 52 : 6539 46.
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996 347 : 1713 27.
10. Althuis MD, Brogan DR, Coates RJ, et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003 88 : 50 7.
11. Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989 20 : 1139 44.
12. Hemminki E. Oral contraceptives and breast cancer. BMJ 1996 313 : 63 4.
13. Olsson H, Jernstrom H, Alm P, et al. Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors. Breast Cancer Res Treat 1996 40 : 187 96.
14. Williams G, Anderson E, Howell A, et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991 48 : 206 10.
15. Ranstam J, Olsson H. Oral contraceptive use among young women in southern Sweden. J Epidemiol Community Health 1993 47 : 32 5.
16. Rimpela AH, Rimpela MK, Kosunen EA. Use of oral contraceptives by adolescents and its consequences in Finland 1981-91. BMJ 1992 305 : 1053 7.
17. Navarrete MA, Maier CM, Falzoni R, et al. Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res 2005 7 : R306 13.
18. Nazario AC, De Lima GR, Simoes MJ, Novo NF. Cell kinetics of the human mammary lobule during the proliferative and secretory phase of the menstrual cycle. Bull Assoc Anat (Nancy) 1995 79 : 23 7.
19. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993 15 : 17 35.
20. Israel R, Mishell DR Jr., Stone SC, Thorneycroft IH, Moyer DL. Single luteal phase serum progesterone assay as an indicator of ovulation. Am J Obstet Gynecol 1972 112 : 1043 6.
21. Bassler R. The morphology of hormone induced structural changes in the female breast. Curr Top Pathol 1970 53 : 1 89.
22. Meyer JS. Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones. Hum Pathol 1977 8 : 67 81.
23. Izquierdo JN, Gibbs SJ. Turnover of cell-renewing populations undergoing circadian rhythms in cell proliferation. Cell Tissue Kinet 1974 7 : 99 111.
24. Masters JR, Drife JO, Scarisbrick JJ. Cyclic variation of DNA synthesis in human breast epithelium. J Natl Cancer Inst 1977 58 : 1263 5.
25. Bates SE, Valverius EM, Ennis BW, et al. Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology 1990 126 : 596 607.
26. Dell'Aquila ML, Pigott DA, Bonaquist DL, Gaffney EV. A factor from plasma-derived human serum that inhibits the growth of the mammary cell line MCF-7: characterization and purification. J Natl Cancer Inst 1984 72 : 291 8.
27. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997 386 : 761.
28. Nilsson S, Gustafsson JA. Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res 2000 2 : 360 6.
29. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997 277 : 1508 10.
30. Soto AM, Sonnenschein C. Cell proliferation of estrogen-sensitive cells: the case for negative control. Endocr Rev 1987 8 : 44 52.
31. Speirs V, Skliris GP, Burdall SE, Carder PJ. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 2002 55 : 371 4.
32. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002 296 : 1642 4.
33. Means AR, Comstock JP, Rosenfeld GC, O'Malley BW. Ovalbumin messenger RNA of chick oviduct: partial characterization, estrogen dependence, and translation in vitro. Proc Natl Acad Sci USA 1972 69 : 1146 50.
34. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999 140 : 5566 78.
35. Ewan KB, Shyamala G, Ravani SA, et al. Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation. Am J Pathol 2002 160 : 2081 93.
36. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem 1998 273 : 1 4.
37. Kuperwasser C, Pinkas J, Hurlbut GD, Naber SP, Jerry DJ. Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. Cancer Res 2000 60 : 2723 9.